Mereo BioPharma sets up shop with Novartis spin-offs
This article was originally published in Scrip
Executive Summary
New UK specialist biotech company Mereo BioPharma is on the look-out for a handful of further promising products to add to the three clinical-stage products it has just acquired from Novartis, according to company CEO Denise Scots-Knight.
You may also be interested in...
US FDA's New Hypogonadism Guidance Focuses On Non-Testosterone Products
Draft is intended to inform development of non-testosterone products such as aromatase inhibitors or estrogen receptor agonists.
What Progress In The Rare Disease, Osteogenesis Imperfecta?
Two-year-old biotech Mereo BioPharma Group plc is planning to start a pivotal Phase IIb study in osteogenesis imperfecta patients in the first-half of this year with its anti-sclerostin antibody, BPS-804, and if the results are promising, EU patients could gain early access through the region’s adaptive pathways program.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.